Phase 2b study to evaluate the rate of onset of action of RDX227675 along with safety and efficacy in patients with chronic kidney disease (CKD) with or without heart failure (HF)

Trial Profile

Phase 2b study to evaluate the rate of onset of action of RDX227675 along with safety and efficacy in patients with chronic kidney disease (CKD) with or without heart failure (HF)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs RDX 7675 (Primary)
  • Indications Hyperkalaemia; Kidney disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Nov 2017 According to a company media release, Ardelyx has made the decision to discontinue development of RDX7675, including both the onset-of-action and Phase 3 studies because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial.
    • 21 Nov 2017 Status changed from recruiting to discontinued according to an Ardelyx media release.
    • 07 Nov 2017 According to an Ardelyx media release, the company anticipates providing an update from the study by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top